Add time:07/22/2019 Source:sciencedirect.com
ObjectiveTo evaluate the toxicity and efficacy of irinotecan plus cisplatin neoadjuvant chemotherapy (NACT) for cervical cancer.
We also recommend Trading Suppliers and Manufacturers of Irinotecan hydrochloride (cas 100286-90-6). Pls Click Website Link as below: cas 100286-90-6 suppliers
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View